FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2116346992> ?p ?o ?g. }

• W2116346992 endingPage "1153" @default.
• W2116346992 startingPage "1151" @default.
• W2116346992 abstract "Study objective: To determine whether the excreted metabolites of naloxone hydrochloride cause positive urine toxicologic screens for opiates. Design: Prospective, randomized, double-blinded human protocol. Setting: Urban Level I military emergency department. Participants: Fourteen adult volunteers who took no routinemedications, were not pregnant, had no known sensitivity to naloxone, and who were negative for a pretest urine and serum toxicologic screen. Interventions: We administered either 2 or 4 mg IV naloxoneto 14 subjects. Urine drug screening was obtained before administration and at 60 minutes, 6 hours, and 48 hours after administration. Results: All urine drug screens using the enzyme-multipliedimmunoassay technique were negative for opiates at both dosage levels. The sample size of 14 yielded a power of more than .99 to detect the difference between positive and negative samples. Conclusion: Although the metabolites of naloxone hydrochloride are similar in structure to oxymorphone and are excreted in human urine for several days, naloxone was not associated with a positive enzymatic urine screen for opiates. Study objective: To determine whether the excreted metabolites of naloxone hydrochloride cause positive urine toxicologic screens for opiates. Design: Prospective, randomized, double-blinded human protocol. Setting: Urban Level I military emergency department. Participants: Fourteen adult volunteers who took no routinemedications, were not pregnant, had no known sensitivity to naloxone, and who were negative for a pretest urine and serum toxicologic screen. Interventions: We administered either 2 or 4 mg IV naloxoneto 14 subjects. Urine drug screening was obtained before administration and at 60 minutes, 6 hours, and 48 hours after administration. Results: All urine drug screens using the enzyme-multipliedimmunoassay technique were negative for opiates at both dosage levels. The sample size of 14 yielded a power of more than .99 to detect the difference between positive and negative samples. Conclusion: Although the metabolites of naloxone hydrochloride are similar in structure to oxymorphone and are excreted in human urine for several days, naloxone was not associated with a positive enzymatic urine screen for opiates." @default.
• W2116346992 created "2016-06-24" @default.
• W2116346992 creator A5008237198 @default.
• W2116346992 creator A5056088852 @default.
• W2116346992 creator A5071157551 @default.
• W2116346992 creator A5074017154 @default.
• W2116346992 date "1994-12-01" @default.
• W2116346992 modified "2023-10-18" @default.
• W2116346992 title "Does naloxone cause a positive urine opiate screen?" @default.
• W2116346992 cites W163248465 @default.
• W2116346992 cites W170838176 @default.
• W2116346992 cites W1878900381 @default.
• W2116346992 cites W1948769377 @default.
• W2116346992 cites W2011187641 @default.
• W2116346992 cites W2085804169 @default.
• W2116346992 cites W2171187460 @default.
• W2116346992 doi "https://doi.org/10.1016/s0196-0644(94)70247-0" @default.
• W2116346992 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/7978599" @default.
• W2116346992 hasPublicationYear "1994" @default.
• W2116346992 type Work @default.
• W2116346992 sameAs 2116346992 @default.
• W2116346992 citedByCount "5" @default.
• W2116346992 crossrefType "journal-article" @default.
• W2116346992 hasAuthorship W2116346992A5008237198 @default.
• W2116346992 hasAuthorship W2116346992A5056088852 @default.
• W2116346992 hasAuthorship W2116346992A5071157551 @default.
• W2116346992 hasAuthorship W2116346992A5074017154 @default.
• W2116346992 hasConcept C118552586 @default.
• W2116346992 hasConcept C126322002 @default.
• W2116346992 hasConcept C170493617 @default.
• W2116346992 hasConcept C2778140631 @default.
• W2116346992 hasConcept C2778750930 @default.
• W2116346992 hasConcept C2779225474 @default.
• W2116346992 hasConcept C2780026642 @default.
• W2116346992 hasConcept C2780724011 @default.
• W2116346992 hasConcept C2781063702 @default.
• W2116346992 hasConcept C2908806481 @default.
• W2116346992 hasConcept C42219234 @default.
• W2116346992 hasConcept C71924100 @default.
• W2116346992 hasConceptScore W2116346992C118552586 @default.
• W2116346992 hasConceptScore W2116346992C126322002 @default.
• W2116346992 hasConceptScore W2116346992C170493617 @default.
• W2116346992 hasConceptScore W2116346992C2778140631 @default.
• W2116346992 hasConceptScore W2116346992C2778750930 @default.
• W2116346992 hasConceptScore W2116346992C2779225474 @default.
• W2116346992 hasConceptScore W2116346992C2780026642 @default.
• W2116346992 hasConceptScore W2116346992C2780724011 @default.
• W2116346992 hasConceptScore W2116346992C2781063702 @default.
• W2116346992 hasConceptScore W2116346992C2908806481 @default.
• W2116346992 hasConceptScore W2116346992C42219234 @default.
• W2116346992 hasConceptScore W2116346992C71924100 @default.
• W2116346992 hasIssue "6" @default.
• W2116346992 hasLocation W21163469921 @default.
• W2116346992 hasLocation W21163469922 @default.
• W2116346992 hasOpenAccess W2116346992 @default.
• W2116346992 hasPrimaryLocation W21163469921 @default.
• W2116346992 hasRelatedWork W1981776568 @default.
• W2116346992 hasRelatedWork W1982391956 @default.
• W2116346992 hasRelatedWork W1992066728 @default.
• W2116346992 hasRelatedWork W2014137948 @default.
• W2116346992 hasRelatedWork W2028657130 @default.
• W2116346992 hasRelatedWork W2046330056 @default.
• W2116346992 hasRelatedWork W2065066854 @default.
• W2116346992 hasRelatedWork W2079527505 @default.
• W2116346992 hasRelatedWork W2116346992 @default.
• W2116346992 hasRelatedWork W2147096918 @default.
• W2116346992 hasVolume "24" @default.
• W2116346992 isParatext "false" @default.
• W2116346992 isRetracted "false" @default.
• W2116346992 magId "2116346992" @default.
• W2116346992 workType "article" @default.